1Key Laboratory of Precision and Intelligent Chemistry, University of Science and Technology of China(USTC), Hefei, China
2MR Research, Beijing, China
Presenting Author: Sijie Yuan
Synopsis
Motivation:
Goals:
Approach:
Results:
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public on 13 May 2028.
To request or purchase access, contact the ISMRM Central Office at support@ismrm.org.
1. Valle-Inclan, J. E.; De Noon, S.; Trevers, K., et al. Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. Cell. 2025, 188 (2), 352-370. e322. doi: 10.1016/j.cell.2024.12.005 [doi]
2. Meltzer, P. S.; Helman, L. J. New horizons in the treatment of osteosarcoma. New England Journal of Medicine. 2021, 385 (22), 2066-2076. doi: 10.1056/NEJMra2103423 [doi]
3. Zhuang, J.; Liu, X.; Yang, Y., et al. Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use. Journal of Cellular and Molecular Medicine. 2021, 25 (12), 5372-5380. doi: 10.1111/jcmm.16548 [doi]
4. Koppula, P.; Zhuang, L.; Gan, B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein & cell. 2021, 12 (8), 599-620. doi: 10.1007/s13238-020-00789-5 [doi]
5. Longo, D. L.; Carella, A.; Corrado, A., et al. A snapshot of the vast array of diamagnetic CEST MRI contrast agents. NMR in Biomedicine. 2023, 36 (6), e4715. doi: 10.1002/nbm.4715 [doi]